Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2875358 with or without erlotinib in MET-positive NSCLC after acquired resistance to erlotinib
NL-OMON38762Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2013
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing LY2875358 + erlotinib with LY2875358 monotherapy (2 arms). Primary endpoints: Overall response rate and Overall response rate in MET-high subgroup. Started Oct 2013; status: active, not recruiting.
02
Drugs
emibetuzumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON38762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38762.